Cargando…

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

Classical Hodgkin lymphoma (cHL) has achieved high cure rates as a result of recent advancements in treatment. However, recurring or relapsed illness still poses a therapeutic challenge. Immune checkpoint inhibitor pembrolizumab, which targets PD-1, is now being commonly used as part of immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hossain, Md Fahad, Kharel, Manish, Akter, Mahfuza, Parajuli, Bibek, Yadav, Indresh, Mandal, Nitesh, Mandal, Anjali, Aziz, Syed Nurul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602819/ https://www.ncbi.nlm.nih.gov/pubmed/37900494 http://dx.doi.org/10.7759/cureus.46032

Ejemplares similares

Post-COVID-19 Illness Trend in a Local Community in Bangladesh
por: Hossain, Md Fahad, et al.
Publicado: (2023)

Prevalence of Electrolyte Imbalance in Patients With Acute Stroke: A Systematic Review
por: Hossain, Md Fahad, et al.
Publicado: (2023)

The Safety and Efficacy of Cryotherapy in the Prevention of Paclitaxel-Induced Neuropathy: A Systematic Review
por: Hossain, Md Fahad, et al.
Publicado: (2023)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

A Case of Classical Hodgkin’s Lymphoma Presenting With Intractable Pruritus
por: Benn, Gregory, et al.
Publicado: (2021)

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2019)

A Case Report on the Rare Presentation of the Primary Spinal Epidural Non-Hodgkin's Lymphoma
por: Mandal, Shobha, et al.
Publicado: (2022)

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015)

Hemophagocytic Lymphohistiocytosis as the Presenting Manifestation of Relapsed Classic Hodgkin’s Lymphoma in the Presence of Concurrent Human Immunodeficiency Virus, Genital Herpes, Epstein-Barr Virus and Mycobacterium Avium Complex Infection
por: Siddiqui, Raheel S, et al.
Publicado: (2020)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma
por: Le‐Nguyen, Alexandre, et al.
Publicado: (2021)

Association of Celiac Disease With Pembrolizumab
por: Sethi, Ashish, et al.
Publicado: (2021)

Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin’s Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®)
por: Shenouda, Mina, et al.
Publicado: (2019)

Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
por: Kanwal, Bushra
Publicado: (2021)

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
por: Laliberté, François, et al.
Publicado: (2020)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2018)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)

Concurrent Occurrence of Neuropsychiatric Systemic Lupus Erythematosus and Sarcoidosis: A Case Report
por: Kharel, Manish, et al.
Publicado: (2023)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Acute Pancreatitis Secondary to Pembrolizumab-Induced Hypertriglyceridemia
por: Ashfaq, Ammar, et al.
Publicado: (2023)

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease
por: Lüke, Florian, et al.
Publicado: (2021)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
por: Fromm, Jonathan, et al.
Publicado: (2022)

The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor
por: Al Attar, Layth, et al.
Publicado: (2018)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
por: Massaro, Fulvio, et al.
Publicado: (2022)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

A Pattern of Antibiotic Resistance in Gram-Negative Rods Causing Urinary Tract Infection in Adults
por: Ali, Syed Asad, et al.
Publicado: (2021)

Pituitary apoplexy associated with bacterial meningitis: Diagnostic dilemma
por: Kharel, Manish, et al.
Publicado: (2023)

Cannulation Strategies in Type A Aortic Dissection: Overlooked Details and Novel Approaches
por: Yadav, Indresh, et al.
Publicado: (2023)

Primary Refractory and Relapsed Classical Hodgkin Lymphoma - Significance of Differential CD15 Expression in Hodgkin-Reed-Sternberg Cells
por: Benharroch, Daniel, et al.
Publicado: (2012)

Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy
por: Manam, Rupesh, et al.
Publicado: (2018)

Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy
por: Dalal, Fazal, et al.
Publicado: (2022)

Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived
por: Crane, Genevieve M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7dc58gc18h7pbeirp1cch0sc9n